These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38934345)

  • 1. Successful treatment with guanfacine in a long-COVID case manifesting marked cognitive impairment.
    Kondo T; Higa R; Kuniba M; Shinzato H; Takaesu Y
    Neuropsychopharmacol Rep; 2024 Jun; ():. PubMed ID: 38934345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Cognitive Function After Kidney Transplantation: A Longitudinal Cohort Study.
    Gupta A; Mahnken JD; Bernal J; Sharma P; Lepping RJ; Montgomery RN; Johnson DK; Parks A; Burns JM; Drew DA; Sarnak MJ; Brooks WM
    Am J Kidney Dis; 2024 Jul; 84(1):28-37.e1. PubMed ID: 38423160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
    Kollins SH; López FA; Vince BD; Turnbow JM; Farrand K; Lyne A; Wigal SB; Roth T
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it).
    Cha DS; Carmona NE; Mansur RB; Lee Y; Park HJ; Rodrigues NB; Subramaniapillai M; Rosenblat JD; Pan Z; Lee JH; Lee J; Almatham F; Alageel A; Shekotikhina M; Zhou AJ; Rong C; Harrison J; McIntyre RS
    Scand J Pain; 2017 Apr; 15():62-67. PubMed ID: 28850348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments.
    Hoang K; Watt H; Golemme M; Perry RJ; Ritchie C; Wilson D; Pickett J; Fox C; Howard R; Malhotra PA
    Trials; 2022 Aug; 23(1):623. PubMed ID: 35915506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The characteristic of cognitive impairments in patients with bipolar II depression and its association with N-acetyl aspartate of the prefrontal white matter.
    Zhong S; Lai S; Yue J; Wang Y; Shan Y; Liao X; Chen J; Li Z; Chen G; Chen F; Jia Y
    Ann Transl Med; 2020 Nov; 8(21):1457. PubMed ID: 33313202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction: Validation in Patients With Major Depressive Disorder.
    McIntyre RS; Best MW; Bowie CR; Carmona NE; Cha DS; Lee Y; Subramaniapillai M; Mansur RB; Barry H; Baune BT; Culpepper L; Fossati P; Greer TL; Harmer C; Klag E; Lam RW; Wittchen HU; Harrison J
    J Clin Psychiatry; 2017 Jul; 78(7):873-881. PubMed ID: 28858441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive Deficits in the THINC-Integrated Tool (THINC-it) Are Associated With Psychosocial Dysfunction in Patients With Major Depressive Disorder.
    Knight MJ; Fourrier C; Lyrtzis E; Aboustate N; Sampson E; Hori H; Mills NT; Baune BT
    J Clin Psychiatry; 2018 Nov; 80(1):. PubMed ID: 30549482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meditation and Music Improve Memory and Cognitive Function in Adults with Subjective Cognitive Decline: A Pilot Randomized Controlled Trial.
    Innes KE; Selfe TK; Khalsa DS; Kandati S
    J Alzheimers Dis; 2017; 56(3):899-916. PubMed ID: 28106552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subjective and Objective Measures of Cognitive Function are Correlated in Persons with Post-COVID-19 Condition: A Secondary Analysis of a Randomized Controlled Trial.
    Kwan ATH; Lakhani M; Le GH; Singh G; Teopiz KM; Ceban F; Nijjar CS; Meshkat S; Badulescu S; Ho R; Rhee TG; Vincenzo JDD; Gill H; McIntyre RS
    medRxiv; 2024 Mar; ():. PubMed ID: 38562707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The THINC-it Tool for Cognitive Assessment and Measurement in Major Depressive Disorder: Sensitivity to Change.
    McIntyre RS; Subramaniapillai M; Park C; Zuckerman H; Cao B; Lee Y; Iacobucci M; Nasri F; Fus D; Bowie CR; Tran T; Rosenblat JD; Mansur RB
    Front Psychiatry; 2020; 11():546. PubMed ID: 32670103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
    Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
    Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA; Sikirica V; Weiss MD; Robertson B; Lyne A; Newcorn JH
    CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Planning in amnestic mild cognitive impairment: an fMRI study.
    Lejko N; Tumati S; Opmeer EM; Marsman JC; Reesink FE; De Deyn PP; Aleman A; Ćurčić-Blake B
    Exp Gerontol; 2022 Mar; 159():111673. PubMed ID: 34958871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.
    Newcorn JH; Harpin V; Huss M; Lyne A; Sikirica V; Johnson M; Ramos-Quiroga JA; van Stralen J; Dutray B; Sreckovic S; Bloomfield R; Robertson B
    J Child Psychol Psychiatry; 2016 Jun; 57(6):717-28. PubMed ID: 26871297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSYCHOMETRIC properties of the Chinese version of the THINC-it tool for cognitive symptoms in patients with major depressive disorder.
    Hou Y; Yao S; Hu S; Zhou Q; Han H; Yu X; McIntyre RS; Shi C
    J Affect Disord; 2020 Aug; 273():586-591. PubMed ID: 32560957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.